Published in Cancer Res on December 01, 2004
The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) (2008) 2.30
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 1.30
Prostate cancer stem cells. J Pathol (2009) 1.26
Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiother Oncol (2014) 1.03
Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis (2008) 1.01
Radiation cataracts: mechanisms involved in their long delayed occurrence but then rapid progression. Mol Vis (2008) 0.95
Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl (2014) 0.92
X-ray induced cataract is preceded by LEC loss, and coincident with accumulation of cortical DNA, and ROS; similarities with age-related cataracts. Mol Vis (2010) 0.90
Contributions of Rad9 to tumorigenesis. J Cell Biochem (2012) 0.88
Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate. Int J Cancer (2007) 0.86
ATM sequence variants associate with susceptibility to non-small cell lung cancer. Int J Cancer (2007) 0.86
Polycyclic aromatic hydrocarbon--DNA adducts in prostate and biochemical recurrence after prostatectomy. Clin Cancer Res (2008) 0.85
The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics (2014) 0.84
Gastrointestinal hyperplasia with altered expression of DNA polymerase beta. PLoS One (2009) 0.83
Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis. Cancer Lett (2005) 0.83
Integrin-dependent amplification of the G2 arrest induced by ionizing radiation. Prostate (2006) 0.83
Spontaneous and radiation-induced chromosomal instability and persistence of chromosome aberrations after radiotherapy in lymphocytes from prostate cancer patients. Radiat Environ Biophys (2009) 0.80
Bridge-induced chromosome translocation in yeast relies upon a Rad54/Rdh54-dependent, Pol32-independent pathway. PLoS One (2013) 0.79
Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. Biomed Res Int (2013) 0.79
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocr Relat Cancer (2014) 0.79
XRCC1 Arg399Gln was associated with repair capacity for DNA damage induced by occupational chromium exposure. BMC Res Notes (2012) 0.78
Targeting DNA polymerase ß for therapeutic intervention. Curr Mol Pharmacol (2012) 0.78
Tumor cell death mediated by peptides that recognize branched intermediates of DNA replication and repair. PLoS One (2013) 0.77
Riccardin D Exerts Its Antitumor Activity by Inducing DNA Damage in PC-3 Prostate Cancer Cells In Vitro and In Vivo. PLoS One (2013) 0.77
TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy. World J Urol (2008) 0.76
NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget (2014) 0.76
RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nat Commun (2016) 0.75
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell (2009) 6.77
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Mutations in SUFU predispose to medulloblastoma. Nat Genet (2002) 3.78
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol (2008) 2.66
The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer (2002) 2.57
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol (2004) 2.09
A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics (2005) 2.04
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res (2005) 2.02
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet (2008) 1.98
Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res (2010) 1.97
MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (2011) 1.97
The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell (2003) 1.90
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys (2010) 1.89
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia (2003) 1.64
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer (2003) 1.52
Fourth International Workgroup on Genotoxicity testing: results of the in vivo Comet assay workgroup. Mutat Res (2006) 1.51
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44
Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol (2006) 1.43
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet (2011) 1.42
Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet (2003) 1.41
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proc Natl Acad Sci U S A (2010) 1.40
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol (2008) 1.39
The genetics of osteosarcoma. Sarcoma (2012) 1.33
Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet (2009) 1.33
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Mol Cell (2010) 1.32
Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between rhabdomyosarcoma subtypes. Oncogene (2002) 1.32
Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res (2007) 1.32
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer (2006) 1.29
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res (2008) 1.29
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int (2011) 1.24
The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev (2004) 1.24
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res (2013) 1.24
In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One (2008) 1.24
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23
Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet (2006) 1.23
Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol (2005) 1.22
High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia (2005) 1.22
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol (2004) 1.21
Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. Am J Med Genet A (2006) 1.21
Measurement of oxidative DNA damage induced by mainstream cigarette smoke in cultured NCI-H292 human pulmonary carcinoma cells. Mutat Res (2008) 1.20
Application of microarrays to the analysis of gene expression in cancer. Clin Chem (2002) 1.20
Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res (2006) 1.19
An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest (2005) 1.19
Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit. ACS Nano (2009) 1.19
Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol (2005) 1.18
Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome. Hum Genet (2006) 1.17
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma (2006) 1.17
Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res (2005) 1.16
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (2007) 1.15
Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. J Clin Pathol (2007) 1.14
Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer (2007) 1.14
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol (2010) 1.14
Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol (2006) 1.13
Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol (2009) 1.13
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol (2003) 1.11
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer (2011) 1.11
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther (2009) 1.11
"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res (2010) 1.11
An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer (2005) 1.10
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia (2009) 1.09
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol (2005) 1.08
Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol (2006) 1.08
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol (2009) 1.08
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology (2012) 1.06
PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol (2011) 1.05
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res (2002) 1.04